Prospects for a MERS-CoV spike vaccine.
Identifieur interne : 000828 ( PubMed/Curation ); précédent : 000827; suivant : 000829Prospects for a MERS-CoV spike vaccine.
Auteurs : Yusen Zhou [République populaire de Chine] ; Shibo Jiang [États-Unis] ; Lanying Du [États-Unis]Source :
- Expert review of vaccines [ 1744-8395 ] ; 2018.
Descripteurs français
- KwdFr :
- Animaux, Anticorps neutralisants (immunologie), Coronavirus du syndrome respiratoire du Moyen-Orient (immunologie), Glycoprotéine de spicule des coronavirus (immunologie), Humains, Infections à coronavirus (), Infections à coronavirus (virologie), Liaison aux protéines, Vaccins antiviraux (administration et posologie), Vaccins antiviraux (effets indésirables), Vaccins antiviraux (immunologie).
- MESH :
- administration et posologie : Vaccins antiviraux.
- effets indésirables : Vaccins antiviraux.
- immunologie : Anticorps neutralisants, Coronavirus du syndrome respiratoire du Moyen-Orient, Glycoprotéine de spicule des coronavirus, Vaccins antiviraux.
- virologie : Infections à coronavirus.
- Animaux, Humains, Infections à coronavirus, Liaison aux protéines.
English descriptors
- KwdEn :
- Animals, Antibodies, Neutralizing (immunology), Coronavirus Infections (prevention & control), Coronavirus Infections (virology), Humans, Middle East Respiratory Syndrome Coronavirus (immunology), Protein Binding, Spike Glycoprotein, Coronavirus (immunology), Viral Vaccines (administration & dosage), Viral Vaccines (adverse effects), Viral Vaccines (immunology).
- MESH :
- chemical , administration & dosage : Viral Vaccines.
- chemical , adverse effects : Viral Vaccines.
- chemical , immunology : Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus, Viral Vaccines.
- immunology : Middle East Respiratory Syndrome Coronavirus.
- prevention & control : Coronavirus Infections.
- virology : Coronavirus Infections.
- Animals, Humans, Protein Binding.
Abstract
Six years have passed since Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV), a newly emerging infectious virus, was first reported in 2012. Although MERS-CoV has had a consistently high mortality rate in humans, no vaccines have been approved to prevent MERS-CoV infection in humans. MERS-CoV spike (S) protein is a key target for development of MERS vaccines.
DOI: 10.1080/14760584.2018.1506702
PubMed: 30058403
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000828
Links to Exploration step
pubmed:30058403Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prospects for a MERS-CoV spike vaccine.</title>
<author><name sortKey="Zhou, Yusen" sort="Zhou, Yusen" uniqKey="Zhou Y" first="Yusen" last="Zhou">Yusen Zhou</name>
<affiliation wicri:level="1"><nlm:affiliation>a State Key Laboratory of Pathogen and Biosecurity , Beijing Institute of Microbiology and Epidemiology , Beijing , China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>a State Key Laboratory of Pathogen and Biosecurity , Beijing Institute of Microbiology and Epidemiology , Beijing </wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name>
<affiliation wicri:level="1"><nlm:affiliation>b Lindsley F. Kimball Research Institute, New York Blood Center , New York , NY , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>b Lindsley F. Kimball Research Institute, New York Blood Center , New York , NY </wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Du, Lanying" sort="Du, Lanying" uniqKey="Du L" first="Lanying" last="Du">Lanying Du</name>
<affiliation wicri:level="1"><nlm:affiliation>b Lindsley F. Kimball Research Institute, New York Blood Center , New York , NY , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>b Lindsley F. Kimball Research Institute, New York Blood Center , New York , NY </wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2018">2018</date>
<idno type="RBID">pubmed:30058403</idno>
<idno type="pmid">30058403</idno>
<idno type="doi">10.1080/14760584.2018.1506702</idno>
<idno type="wicri:Area/PubMed/Corpus">000828</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000828</idno>
<idno type="wicri:Area/PubMed/Curation">000828</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000828</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Prospects for a MERS-CoV spike vaccine.</title>
<author><name sortKey="Zhou, Yusen" sort="Zhou, Yusen" uniqKey="Zhou Y" first="Yusen" last="Zhou">Yusen Zhou</name>
<affiliation wicri:level="1"><nlm:affiliation>a State Key Laboratory of Pathogen and Biosecurity , Beijing Institute of Microbiology and Epidemiology , Beijing , China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>a State Key Laboratory of Pathogen and Biosecurity , Beijing Institute of Microbiology and Epidemiology , Beijing </wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name>
<affiliation wicri:level="1"><nlm:affiliation>b Lindsley F. Kimball Research Institute, New York Blood Center , New York , NY , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>b Lindsley F. Kimball Research Institute, New York Blood Center , New York , NY </wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Du, Lanying" sort="Du, Lanying" uniqKey="Du L" first="Lanying" last="Du">Lanying Du</name>
<affiliation wicri:level="1"><nlm:affiliation>b Lindsley F. Kimball Research Institute, New York Blood Center , New York , NY , USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>b Lindsley F. Kimball Research Institute, New York Blood Center , New York , NY </wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Expert review of vaccines</title>
<idno type="eISSN">1744-8395</idno>
<imprint><date when="2018" type="published">2018</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antibodies, Neutralizing (immunology)</term>
<term>Coronavirus Infections (prevention & control)</term>
<term>Coronavirus Infections (virology)</term>
<term>Humans</term>
<term>Middle East Respiratory Syndrome Coronavirus (immunology)</term>
<term>Protein Binding</term>
<term>Spike Glycoprotein, Coronavirus (immunology)</term>
<term>Viral Vaccines (administration & dosage)</term>
<term>Viral Vaccines (adverse effects)</term>
<term>Viral Vaccines (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Anticorps neutralisants (immunologie)</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient (immunologie)</term>
<term>Glycoprotéine de spicule des coronavirus (immunologie)</term>
<term>Humains</term>
<term>Infections à coronavirus ()</term>
<term>Infections à coronavirus (virologie)</term>
<term>Liaison aux protéines</term>
<term>Vaccins antiviraux (administration et posologie)</term>
<term>Vaccins antiviraux (effets indésirables)</term>
<term>Vaccins antiviraux (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Neutralizing</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps neutralisants</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Vaccins antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Humans</term>
<term>Protein Binding</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Humains</term>
<term>Infections à coronavirus</term>
<term>Liaison aux protéines</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Six years have passed since Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV), a newly emerging infectious virus, was first reported in 2012. Although MERS-CoV has had a consistently high mortality rate in humans, no vaccines have been approved to prevent MERS-CoV infection in humans. MERS-CoV spike (S) protein is a key target for development of MERS vaccines.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30058403</PMID>
<DateCompleted><Year>2019</Year>
<Month>01</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>03</Month>
<Day>09</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-8395</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>17</Volume>
<Issue>8</Issue>
<PubDate><Year>2018</Year>
<Month>08</Month>
</PubDate>
</JournalIssue>
<Title>Expert review of vaccines</Title>
<ISOAbbreviation>Expert Rev Vaccines</ISOAbbreviation>
</Journal>
<ArticleTitle>Prospects for a MERS-CoV spike vaccine.</ArticleTitle>
<Pagination><MedlinePgn>677-686</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1080/14760584.2018.1506702</ELocationID>
<Abstract><AbstractText Label="INTRODUCTION">Six years have passed since Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV), a newly emerging infectious virus, was first reported in 2012. Although MERS-CoV has had a consistently high mortality rate in humans, no vaccines have been approved to prevent MERS-CoV infection in humans. MERS-CoV spike (S) protein is a key target for development of MERS vaccines.</AbstractText>
<AbstractText Label="AREAS COVERED">In this review, we illustrate the structure and function of S protein as a vaccine target, describe available animal models for evaluating MERS vaccines, and summarize recent progress on MERS-CoV S-based vaccines, focusing on their ability to elicit antibody and/or cellular immune responses, neutralizing antibodies, and protection against MERS-CoV infection in different models. Prospects for future MERS-CoV S-based vaccines are discussed.</AbstractText>
<AbstractText Label="EXPERT COMMENTARY">The majority of MERS vaccines under development are based on MERS-CoV S protein, including full-length S, S1, and receptor-binding domain (RBD). While it is essential to evaluate the safety of full-length S and S1-based MERS vaccines, further improvement of the efficacy of RBD-based vaccines using novel strategies would be necessary. Overall, this review provides informative guidance for designing and developing safe and effective MERS vaccines based on viral S protein.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhou</LastName>
<ForeName>Yusen</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>a State Key Laboratory of Pathogen and Biosecurity , Beijing Institute of Microbiology and Epidemiology , Beijing , China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jiang</LastName>
<ForeName>Shibo</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>b Lindsley F. Kimball Research Institute, New York Blood Center , New York , NY , USA.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>c Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology , Fudan University , Shanghai , China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Du</LastName>
<ForeName>Lanying</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>b Lindsley F. Kimball Research Institute, New York Blood Center , New York , NY , USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>R01 AI137472</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 AI139092</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R21 AI128311</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2018</Year>
<Month>08</Month>
<Day>09</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Expert Rev Vaccines</MedlineTA>
<NlmUniqueID>101155475</NlmUniqueID>
<ISSNLinking>1476-0584</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">MERS</Keyword>
<Keyword MajorTopicYN="Y">MERS-CoV</Keyword>
<Keyword MajorTopicYN="Y">immune responses</Keyword>
<Keyword MajorTopicYN="Y">neutralizing antibodies</Keyword>
<Keyword MajorTopicYN="Y">protection</Keyword>
<Keyword MajorTopicYN="Y">receptor-binding domain</Keyword>
<Keyword MajorTopicYN="Y">spike protein</Keyword>
<Keyword MajorTopicYN="Y">vaccine</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year>
<Month>7</Month>
<Day>31</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2019</Year>
<Month>1</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2018</Year>
<Month>7</Month>
<Day>31</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">30058403</ArticleId>
<ArticleId IdType="doi">10.1080/14760584.2018.1506702</ArticleId>
<ArticleId IdType="pmc">PMC6355461</ArticleId>
<ArticleId IdType="mid">NIHMS1514617</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Virol. 2018 Aug 29;92(18):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29950421</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2014 Oct 14;32(45):5975-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25192975</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2013 Oct 8;110(41):16598-603</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24062443</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28807998</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Emerg Infect Dis. 2016 Apr;22(4):647-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26981708</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet Infect Dis. 2018 Apr;18(4):410-418</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29329957</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Sci Transl Med. 2016 Feb 17;8(326):326ra21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26888429</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2014 Apr 11;32(18):2100-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24560617</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Commun. 2014;5:3067</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24473083</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS One. 2015 Dec 23;10(12):e0145561</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26701103</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2018 Apr 27;92(10):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29514901</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2017 Jan 3;91(2):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27807241</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS Pathog. 2017 Jun 26;13(6):e1006474</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28651017</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2013 Aug 8;500(7461):227-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23831647</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2013 Nov;87(21):11950-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23986586</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2015 Apr;89(7):3659-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25589660</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2018 Mar 27;36(14):1853-1862</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29496347</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Oncotarget. 2017 Feb 21;8(8):12686-12694</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27050368</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Sci Rep. 2017 Sep 12;7(1):11362</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28900197</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2016 Dec 16;91(1):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27795435</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2017 Jun 27;35(30):3780-3788</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28579232</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2016 Dec 16;91(1):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27795425</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antiviral Res. 2017 Jul;143:30-37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28389142</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Viruses. 2016 Aug 19;8(8):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27548203</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2012 Nov 8;367(19):1814-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Rev Microbiol. 2009 Mar;7(3):226-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19198616</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2015 Oct 07;90(1):57-67</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26446606</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>One Health. 2017 Mar 10;3:41-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28616502</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Commun. 2015 Jul 28;6:7712</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26218507</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2013 Sep;87(17):9939-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23824801</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2015 Feb;89(4):1954-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25428871</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Infect Dis. 2016 May 15;213(10):1557-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26941283</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Cell Mol Immunol. 2016 Mar;13(2):180-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25640653</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Immunology. 2015 Aug;145(4):476-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25762305</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Immunity. 2016 Jun 21;44(6):1379-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27287409</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Emerg Microbes Infect. 2017 Jun 7;6(6):e51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28588290</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8738-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26124093</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Expert Rev Vaccines. 2016 Sep;15(9):1123-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26985862</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2017 Apr 11;35(16):2069-2075</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28314561</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Viral Immunol. 2014 Dec;27(10):543-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25387086</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2013 Mar 14;495(7440):251-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23486063</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>mBio. 2017 Apr 4;8(2):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28377531</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Infect Dis. 2014 Jan 15;209(2):236-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24218506</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vector Borne Zoonotic Dis. 2017 Feb;17(2):155-159</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28009529</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Hum Vaccin Immunother. 2017 Jul 3;13(7):1615-1624</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28277821</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2013 Oct;87(19):10777-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23903833</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2015 Aug;89(16):8651-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26018172</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2017 Jan 3;35(1):10-18</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27899228</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Hong Kong Med J. 2012 Feb;18 Suppl 2:31-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22311359</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):E3119-E3128</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28348219</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2004 Nov;78(22):12672-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15507655</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2005 Mar 18;23(17-18):2273-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15755610</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Hum Vaccin Immunother. 2015;11(5):1244-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25874632</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Emerg Microbes Infect. 2017 Nov 8;6(11):e101</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29116217</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>NPJ Vaccines. 2017 Oct 16;2:28</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29263883</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2014 May 30;32(26):3169-3174</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24736006</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Microbiol. 2016 Nov 28;2:16226</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27892925</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2013 Aug;87(16):9379-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23785207</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS Pathog. 2014 Aug 21;10(8):e1004250</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25144235</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>mBio. 2017 Aug 22;8(4):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28830941</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Expert Opin Ther Targets. 2017 Feb;21(2):131-143</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27936982</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virus Res. 2015 Apr 16;202:151-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25445336</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2015 Nov;89(22):11654-67</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26355094</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Emerg Infect Dis. 2014 Dec;20(12):1999-2005</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25418529</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4970-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24599590</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antiviral Res. 2018 Feb;150:30-38</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29246504</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2014 Oct 21;32(46):6170-6176</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25240756</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunol. 2006 May 15;176(10):6085-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16670317</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Cell Res. 2013 Aug;23(8):986-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23835475</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS One. 2014 Nov 18;9(11):e112602</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25405618</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 2016 Dec;499:375-382</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27750111</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>EBioMedicine. 2015 Aug 18;2(10):1438-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26629538</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Exp Med. 2008 Jan 21;205(1):7-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18195078</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Infect Dis. 2017 Jun 1;215(11):1702-1705</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28387845</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Euro Surveill. 2017 Mar 16;22(11):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28333616</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>ACS Infect Dis. 2016 May 13;2(5):361-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27627203</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Emerg Microbes Infect. 2017 Jan 4;6(1):e1</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28050021</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2017 Mar 14;35(12):1586-1589</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28237499</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Sci Transl Med. 2015 Aug 19;7(301):301ra132</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26290414</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>mSphere. 2017 Nov 15;2(6):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29152578</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Sci Rep. 2016 Feb 22;6:21878</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26899616</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antiviral Res. 2017 Apr;140:55-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28040513</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Emerg Infect Dis. 2017 Apr;23(4):682-685</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28322710</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS One. 2017 Feb 24;12(2):e0172093</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28234937</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunol. 2005 Apr 15;174(8):4908-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15814718</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Commun. 2016 Nov 22;7:13473</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27874853</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2016 Jan 1;351(6268):77-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26678878</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Emerg Infect Dis. 2016 Nov;22(11):2020-2022</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27606432</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Am J Infect Control. 2018 Feb;46(2):165-168</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28958446</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Adv Exp Med Biol. 2017;972:49-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27966107</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Sci Rep. 2017 Mar 23;7:44875</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28332568</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000828 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000828 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= MersV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:30058403 |texte= Prospects for a MERS-CoV spike vaccine. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:30058403" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a MersV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |